fbpx
Wikipedia

Focal segmental glomerulosclerosis

April 12, 2024

Focal segmental glomerulosclerosis (FSGS) is a histopathologic finding of scarring (sclerosis) of glomeruli and damage to renal podocytes.[2][3] This process damages the filtration function of the kidney, resulting in protein presence in the urine due to protein loss.[3] FSGS is a leading cause of excess protein loss—nephrotic syndrome—in children and adults.[4] Signs and symptoms include proteinuria and edema.[2][5]Kidney failure is a common long-term complication of the disease.[5][6] FSGS can be classified as primary, secondary, or genetic, depending on whether a particular toxic or pathologic stressor or genetic predisposition can be identified as the cause.[7][8][9] Diagnosis is established by renal biopsy,[2][10] and treatment consists of glucocorticoids and other immune-modulatory drugs.[11] Response to therapy is variable, with a significant portion of patients progressing to end-stage kidney failure.[5] An American epidemiological study 20 years ago demonstrated that FSGS is estimated to occur in 7 persons per million, with males and African-Americans at higher risk .[12][13][7]

Focal segmental glomerulosclerosis
Other namesfocal glomerular sclerosis,[1] focal nodular glomerulosclerosis[1]
Light micrograph of focal segmental glomerulosclerosis, hilar variant. Kidney biopsy. PAS stain.
SpecialtyNephrology 

Signs and symptoms edit

The most common symptoms are a result of abnormal loss of protein from the glomerulus of the kidney, and include:[2][5]

  • Frothy urine (due to excess protein)
  • Excess water retention (pitting edema, due to loss of serum albumin)
  • Susceptibility to infection (due to loss of serum antibodies)

Common signs are also due to loss of blood proteins by the glomerulus of the kidney, including:[2][5][10]

Pathophysiology edit

 
The renal glomerulus consists of a set of capillaries from which blood is filtered into Bowman's space. Large molecules, such as proteins, are usually too large to be filtered and instead are retained in the capillaries.

FSGS is primarily a disease of the renal glomerulus, the site of filtration of ions and solutes.[14][15] Podocytes are specialized cells lining the Bowman's capsule that contribute to the filtration barrier, preventing molecules larger than 5 nm from being filtered.[16] FSGS involves damage to the renal podocytes such that larger molecules, most notably proteins, are filtered and lost through the kidney.[17][18] Thus, many of the signs and symptoms of FSGS are related to protein loss.[19]

On histology, FSGS manifests as scarring (sclerosis) to segments of glomeruli; moreover, only a portion of glomeruli are affected.[7][20][21] The focal and segmental nature of disease seen on histology help to distinguish FSGS from other types of glomerular sclerosis.[21]

FSGS can be classified by the putative cause of damage to podocytes. Primary FSGS involves cases in which no cause is readily identifiable.[22] It is presumed that a set of unidentified circulating factors in the blood contribute to podocyte damage in these cases.[22][23]

Secondary FSGS is caused by an identifiable stress or toxin that injures podocytes.[22] Many causes of secondary FSGS contribute to podocyte injury through hyperfiltration, which is a scenario of excess filtration by renal glomeruli.[24] Hyperfiltration can be caused by obesity, diabetes or loss of the contralateral kidney, among other causes.[24]

Secondary FSGS can also be caused by toxins, including anabolic steroids and heroin.[25][26]

A number of genes have been implicated in FSGS. These include: NPHS1, which encodes the protein nephrin that contributes to the filtration barrier;[27] NPHS2, which encodes the protein podocin found in podocytes;[28] and INF2, which encodes the actin-binding protein formin.[29]

The pathogenesis of HIV-associated FSGS is unclear, but may be primarily due to the presence of the G1/G2 risk alleles for APOL1. There is some data to suggest that HIV can infect tubular epithelial cells and podocytes, but much remains to be known.[30]

Diagnosis edit

Diagnosis of FSGS is made by renal biopsy that includes at least fifteen serial cuts with at least eight glomeruli.[31][32] Histologic features include sclerosis (scarring) of a portion (average: 15%) of the glomerular space, with only a portion of glomeruli manifesting any sclerosis.[32]

Other tests helpful in the diagnosis include urine protein, urinalysis, serum albumin, and serum lipids.[2] A clinical picture of proteinuria, low blood protein levels (albumin, antibodies), and high blood cholesterol would support a diagnosis of FSGS, although these do not help to distinguish between FSGS and other causes of proteinuria.[5][10]

Classification edit

 
Micrograph of the collapsing variant of FSGS (collapsing glomerulopathy). A collapsed glomerulus is seen at the top, right-of-centre. PAS stain. Kidney biopsy.
 
Histopathology of collapsing glomerulopathy. (A,B) Periodic Acid Schiff (PAS) and Jones Methenamine Silver (JMS) (40×), respectively show intense podocyte hyperplasia and glomerular tuft collapse. (C) JMS (20×) exhibits microcytic transformation of distal convoluted tubules with accumulations of hyaline material inside of those. (D,E) Fluorescence microscopy (40×) shows, respectively, IgM and C3 trapping in areas of collapse/sclerosis. (F) Semi-fine stained in Toluidine Blue (63×) with collapse of the entire glomerular tuft and hyperplasia of podocytes and dilated Bowman's space. (G,H) Transmission electron microscopy contrasted with Osmium Tetroxide, Lead Citrate and Uranyl in block shows capillary loop collapse with hyalinosis in addition to diffuse fusion and flattening of the pedicels associated with microvillous transformation. (I) Electron microscopy tubes contrasted with osmium tetroxide, lead citrate, and uranyl in block with detail of disorganization of the cytoskeleton in the podocyte cytoplasm, with extensive effacement of the pedicels.[33]

Five mutually exclusive variants of focal segmental glomerulosclerosis may be distinguished by the pathologic findings seen on renal biopsy:[34]

  1. Collapsing variant
  2. Glomerular tip lesion variant
  3. Cellular variant
  4. Perihilar variant
  5. Not otherwise specified (NOS) variant.

Recognition of these variants may have prognostic value in individuals with primary focal segmental glomerulosclerosis. The collapsing variant is associated with higher rate of progression to end-stage renal disease, whereas the glomerular tip lesion variant has a low rate of progression to end-stage renal disease in most patients.[9] The cellular variant shows similar clinical presentation to collapsing and glomerular tip variant but has intermediate outcomes between the other two variants.[9]

Treatment edit

First-line treatment for primary FSGS consists of anti-inflammatory drugs.[11] Specifically, glucocorticoids are begun in patients manifesting with nephrotic-range proteinuria (>3.5 g/day).[35][36] For patients who maintain nephrotic-range proteinuria despite glucocorticoids, or for patients who demonstrate glucocorticoid intolerance, calcineurin inhibitors (e.g., tacrolimus) are initiated.[36] Successful treatment is defined as a drop in proteinuria to sub-nephrotic ranges.[6]

The treatment of secondary FSGS involves addressing the particular toxic or stress agent.[35]

Prognosis edit

The majority of untreated cases of FSGS will progress to end-stage kidney disease.[37] Important prognostic factors include the degree of proteinuria and initial response to therapy.

Patients with nephrotic-range (>3.5 g/day) proteinuria have over a 50% rate of progression to end-stage kidney disease at 10 years.[6] Only 15% of patients with sub-nephrotic ranges of proteinuria progress to end-stage renal failure at 10 years.[6]

Initial response to therapy also dictates long-term outcomes. Those defined as having a "complete response" typically manifest a proteinuria of <300 mg/day; those with a "partial response" manifest a sub-nephrotic range of proteinuria, <3.5 g/day.[38] Either complete or partial response is associated with 80% kidney survival at 10 years, compared with about 50% among non-responsive patients.[38]

Epidemiology edit

FSGS accounts for 35% of all cases of nephrotic syndrome, making it one of the most common causes of nephrotic syndrome in the United States.[8] FSGS accounts for 2% of all cases of kidney failure.[4] African American patients have four times the likelihood of developing FSGS. Men are about two times as likely to develop FSGS compared to women.[12]

Notable cases edit

See also edit

References edit

  1. ^ a b "focal segmental glomerulosclerosis" at Dorland's Medical Dictionary.
  2. ^ a b c d e f Rosenberg, Avi Z.; Kopp, Jeffrey B. (2017-03-07). "Focal Segmental Glomerulosclerosis". Clinical Journal of the American Society of Nephrology. 12 (3): 502–517. doi:10.2215/CJN.05960616. ISSN 1555-9041. PMC 5338705. PMID 28242845.
  3. ^ a b D'Agati V. The many masks of focal segmental glomerulosclerosis. Kidney Int. 1994 Oct;46(4):1223–41. doi: 10.1038/ki.1994.388. PMID 7861720.
  4. ^ a b Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004 Nov;44(5):815–25. PMID 15492947.
  5. ^ a b c d e f Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis. 1995 Apr;25(4):534–42. doi: 10.1016/0272-6386(95)90120-5. PMID 7702047.
  6. ^ a b c d Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis. 1994 Jun;23(6):773–83. doi: 10.1016/s0272-6386(12)80128-4. PMID 8203357.
  7. ^ a b c "Focal segmental glomerulosclerosis (FSGS)". www.kidneyfund.org. 2021-10-28. Retrieved 2023-11-14.
  8. ^ a b Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997. Am J Kidney Dis. 1997 Nov;30(5):621–31. doi: 10.1016/s0272-6386(97)90485-6. PMID 9370176.
  9. ^ a b c Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol. 2015 Feb;11(2):76–87. doi: 10.1038/nrneph.2014.216. Epub 2014 Dec 2. PMID 25447132; PMCID: PMC4772430.
  10. ^ a b c Kiffel J, Rahimzada Y, Trachtman H. Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients. Adv Chronic Kidney Dis. 2011 Sep;18(5):332–8. doi: 10.1053/j.ackd.2011.03.005. PMID 21896374; PMCID: PMC3709971.
  11. ^ a b Campbell KN, Tumlin JA. Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis. Am J Nephrol. 2018;47 Suppl 1(Suppl 1):14–29. doi: 10.1159/000481634. Epub 2018 May 31. PMID 29852493; PMCID: PMC6589822.
  12. ^ a b Tucker JK. Focal segmental glomerulosclerosis in African Americans. Am J Med Sci. 2002 Feb;323(2):90–3. doi: 10.1097/00000441-200202000-00006. PMID 11863085.
  13. ^ Kitiyakara C, Kopp JB, Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003 Mar;23(2):172–82. doi: 10.1053/snep.2003.50025. PMID 12704577.
  14. ^ Wallace MA. Anatomy and physiology of the kidney. AORN J. 1998 Nov;68(5):800, 803–16, 819–20; quiz 821–4. doi: 10.1016/s0001-2092(06)62377-6. PMID 9829131.
  15. ^ Pollak MR, Quaggin SE, Hoenig MP, Dworkin LD. The glomerulus: the sphere of influence. Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1461–9. doi: 10.2215/CJN.09400913. Epub 2014 May 29. PMID 24875196; PMCID: PMC4123398.
  16. ^ Tojo A, Kinugasa S. Mechanisms of glomerular albumin filtration and tubular reabsorption. Int J Nephrol. 2012;2012:481520. doi: 10.1155/2012/481520. Epub 2012 May 20. PMID 22685655; PMCID: PMC3363986.
  17. ^ Nagata M. Podocyte injury and its consequences. Kidney Int. 2016 Jun;89(6):1221–30. doi: 10.1016/j.kint.2016.01.012. Epub 2016 Mar 19. PMID 27165817.
  18. ^ Wang CS, Greenbaum LA. Nephrotic Syndrome. Pediatr Clin North Am. 2019 Feb;66(1):73–85. doi: 10.1016/j.pcl.2018.08.006. PMID 30454752.
  19. ^ "Focal Segmental Glomerulosclerosis (FSGS)". Cleveland Clinic. Retrieved 2022-06-30.
  20. ^ Ichikawa I, Fogo A. Focal segmental glomerulosclerosis. Pediatr Nephrol. 1996 Jun;10(3):374–91. doi: 10.1007/BF00866790. PMID 8792409.
  21. ^ a b Nagata M, Kobayashi N, Hara S. Focal segmental glomerulosclerosis; why does it occur segmentally? Pflugers Arch. 2017 Aug;469(7–8):983–988. doi: 10.1007/s00424-017-2023-x. Epub 2017 Jun 29. PMID 28664408.
  22. ^ a b c De Vriese AS, Sethi S, Nath KA, et al. Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. J Am Soc Nephrol 2018; 29:759.
  23. ^ Rennke HG, Klein PS. Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis. Am J Kidney Dis 1989; 13:443.
  24. ^ a b Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol. 2012 Feb 21;8(5):293–300. doi: 10.1038/nrneph.2012.19. PMID 22349487.
  25. ^ Dubrow A, Mittman N, Ghali V, Flamenbaum W. The changing spectrum of heroin-associated nephropathy. Am J Kidney Dis 1985; 5:36.
  26. ^ Kasiske BL, Crosson JT. Renal disease in patients with massive obesity. Arch Intern Med 1986; 146:1105.
  27. ^ Philippe A, Nevo F, Esquivel EL, Reklaityte D, Gribouval O, Tête MJ, Loirat C, Dantal J, Fischbach M, Pouteil-Noble C, Decramer S, Hoehne M, Benzing T, Charbit M, Niaudet P, Antignac C. Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2008 Oct;19(10):1871–8. doi: 10.1681/ASN.2008010059. Epub 2008 Jul 9. PMID 18614772; PMCID: PMC2551572.
  28. ^ Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet. 2000 Apr;24(4):349–54. doi: 10.1038/74166. Erratum in: Nat Genet 2000 May;25(1):125. PMID 10742096.
  29. ^ Brown EJ, Schlöndorff JS, Becker DJ, Tsukaguchi H, Tonna SJ, Uscinski AL, Higgs HN, Henderson JM, Pollak MR. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet. 2010 Jan;42(1):72–6. doi: 10.1038/ng.505. Epub 2009 Dec 20. Erratum in: Nat Genet. 2010 Apr;42(4):361. Tonna, Stephen J [added]. PMID 20023659; PMCID: PMC2980844.
  30. ^ Chang, Anthony, Robbins & Cotran Pathologic Basis of Disease, Chapter 20, 895–952
  31. ^ Fuiano G, Comi N, Magri P, et al. Serial morphometric analysis of sclerotic lesions in primary "focal" segmental glomerulosclerosis. J Am Soc Nephrol 1996; 7:49.
  32. ^ a b Schwartz MM, Korbet SM. Primary focal segmental glomerulosclerosis: pathology, histological variants, and pathogenesis. Am J Kidney Dis 1993; 22:874.
  33. ^ Cutrim ÉMM, Neves PDMM, Campos MAG, Wanderley DC, Teixeira-Júnior AAL, Muniz MPR; et al. (2022). "Collapsing Glomerulopathy: A Review by the Collapsing Brazilian Consortium". Front Med (Lausanne). 9: 846173. doi:10.3389/fmed.2022.846173. PMC 8927620. PMID 35308512.{{cite journal}}: CS1 maint: multiple names: authors list (link)
    - CC-BY 4.0 license
  34. ^ Thomas DB, Franceschini N, Hogan SL, et al. (2006). "Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants". Kidney Int. 69 (5): 920–6. doi:10.1038/sj.ki.5000160. PMID 16518352.
  35. ^ a b Chen YM, Liapis H. Focal segmental glomerulosclerosis: molecular genetics and targeted therapies. BMC Nephrol. 2015 Jul 9;16:101. doi: 10.1186/s12882-015-0090-9. PMID 26156092; PMCID: PMC4496884.
  36. ^ a b Raina R, Wang J, Sharma A, Chakraborty R. Extracorporeal Therapies in the Treatment of Focal Segmental Glomerulosclerosis. Blood Purif. 2020;49(5):513–523. doi: 10.1159/000506277. Epub 2020 Feb 19. PMID 32074606.
  37. ^ Deegens JK, Assmann KJ, Steenbergen EJ, Hilbrands LB, Gerlag PG, Jansen JL, Wetzels JF. Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients? Neth J Med. 2005 Nov;63(10):393–8. PMID 16301760.
  38. ^ a b Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005 Apr;16(4):1061–8. doi: 10.1681/ASN.2004070593. Epub 2005 Feb 16. PMID 15716334.

External links edit

April 12, 2024
focal, segmental, glomerulosclerosis, fsgs, histopathologic, finding, scarring, sclerosis, glomeruli, damage, renal, podocytes, this, process, damages, filtration, function, kidney, resulting, protein, presence, urine, protein, loss, fsgs, leading, cause, exce. Focal segmental glomerulosclerosis FSGS is a histopathologic finding of scarring sclerosis of glomeruli and damage to renal podocytes 2 3 This process damages the filtration function of the kidney resulting in protein presence in the urine due to protein loss 3 FSGS is a leading cause of excess protein loss nephrotic syndrome in children and adults 4 Signs and symptoms include proteinuria and edema 2 5 Kidney failure is a common long term complication of the disease 5 6 FSGS can be classified as primary secondary or genetic depending on whether a particular toxic or pathologic stressor or genetic predisposition can be identified as the cause 7 8 9 Diagnosis is established by renal biopsy 2 10 and treatment consists of glucocorticoids and other immune modulatory drugs 11 Response to therapy is variable with a significant portion of patients progressing to end stage kidney failure 5 An American epidemiological study 20 years ago demonstrated that FSGS is estimated to occur in 7 persons per million with males and African Americans at higher risk 12 13 7 Focal segmental glomerulosclerosisOther namesfocal glomerular sclerosis 1 focal nodular glomerulosclerosis 1 Light micrograph of focal segmental glomerulosclerosis hilar variant Kidney biopsy PAS stain SpecialtyNephrology Contents 1 Signs and symptoms 2 Pathophysiology 3 Diagnosis 3 1 Classification 4 Treatment 5 Prognosis 6 Epidemiology 7 Notable cases 8 See also 9 References 10 External linksSigns and symptoms editThe most common symptoms are a result of abnormal loss of protein from the glomerulus of the kidney and include 2 5 Frothy urine due to excess protein Excess water retention pitting edema due to loss of serum albumin Susceptibility to infection due to loss of serum antibodies Common signs are also due to loss of blood proteins by the glomerulus of the kidney including 2 5 10 Protein in the urine often in the nephrotic syndrome range of gt 3 5 g day Low serum albumin lt 3 5 g dl Low serum antibodies High serum cholesterol compensatory by the liver to compensate for low serum oncotic pressure Fatty casts in the urine secondary to hypercholesterolemia Pathophysiology edit nbsp The renal glomerulus consists of a set of capillaries from which blood is filtered into Bowman s space Large molecules such as proteins are usually too large to be filtered and instead are retained in the capillaries FSGS is primarily a disease of the renal glomerulus the site of filtration of ions and solutes 14 15 Podocytes are specialized cells lining the Bowman s capsule that contribute to the filtration barrier preventing molecules larger than 5 nm from being filtered 16 FSGS involves damage to the renal podocytes such that larger molecules most notably proteins are filtered and lost through the kidney 17 18 Thus many of the signs and symptoms of FSGS are related to protein loss 19 On histology FSGS manifests as scarring sclerosis to segments of glomeruli moreover only a portion of glomeruli are affected 7 20 21 The focal and segmental nature of disease seen on histology help to distinguish FSGS from other types of glomerular sclerosis 21 FSGS can be classified by the putative cause of damage to podocytes Primary FSGS involves cases in which no cause is readily identifiable 22 It is presumed that a set of unidentified circulating factors in the blood contribute to podocyte damage in these cases 22 23 Secondary FSGS is caused by an identifiable stress or toxin that injures podocytes 22 Many causes of secondary FSGS contribute to podocyte injury through hyperfiltration which is a scenario of excess filtration by renal glomeruli 24 Hyperfiltration can be caused by obesity diabetes or loss of the contralateral kidney among other causes 24 Secondary FSGS can also be caused by toxins including anabolic steroids and heroin 25 26 A number of genes have been implicated in FSGS These include NPHS1 which encodes the protein nephrin that contributes to the filtration barrier 27 NPHS2 which encodes the protein podocin found in podocytes 28 and INF2 which encodes the actin binding protein formin 29 The pathogenesis of HIV associated FSGS is unclear but may be primarily due to the presence of the G1 G2 risk alleles for APOL1 There is some data to suggest that HIV can infect tubular epithelial cells and podocytes but much remains to be known 30 Diagnosis editDiagnosis of FSGS is made by renal biopsy that includes at least fifteen serial cuts with at least eight glomeruli 31 32 Histologic features include sclerosis scarring of a portion average 15 of the glomerular space with only a portion of glomeruli manifesting any sclerosis 32 Other tests helpful in the diagnosis include urine protein urinalysis serum albumin and serum lipids 2 A clinical picture of proteinuria low blood protein levels albumin antibodies and high blood cholesterol would support a diagnosis of FSGS although these do not help to distinguish between FSGS and other causes of proteinuria 5 10 Classification edit nbsp Micrograph of the collapsing variant of FSGS collapsing glomerulopathy A collapsed glomerulus is seen at the top right of centre PAS stain Kidney biopsy nbsp Histopathology of collapsing glomerulopathy A B Periodic Acid Schiff PAS and Jones Methenamine Silver JMS 40 respectively show intense podocyte hyperplasia and glomerular tuft collapse C JMS 20 exhibits microcytic transformation of distal convoluted tubules with accumulations of hyaline material inside of those D E Fluorescence microscopy 40 shows respectively IgM and C3 trapping in areas of collapse sclerosis F Semi fine stained in Toluidine Blue 63 with collapse of the entire glomerular tuft and hyperplasia of podocytes and dilated Bowman s space G H Transmission electron microscopy contrasted with Osmium Tetroxide Lead Citrate and Uranyl in block shows capillary loop collapse with hyalinosis in addition to diffuse fusion and flattening of the pedicels associated with microvillous transformation I Electron microscopy tubes contrasted with osmium tetroxide lead citrate and uranyl in block with detail of disorganization of the cytoskeleton in the podocyte cytoplasm with extensive effacement of the pedicels 33 Five mutually exclusive variants of focal segmental glomerulosclerosis may be distinguished by the pathologic findings seen on renal biopsy 34 Collapsing variant Glomerular tip lesion variant Cellular variant Perihilar variant Not otherwise specified NOS variant Recognition of these variants may have prognostic value in individuals with primary focal segmental glomerulosclerosis The collapsing variant is associated with higher rate of progression to end stage renal disease whereas the glomerular tip lesion variant has a low rate of progression to end stage renal disease in most patients 9 The cellular variant shows similar clinical presentation to collapsing and glomerular tip variant but has intermediate outcomes between the other two variants 9 Treatment editFirst line treatment for primary FSGS consists of anti inflammatory drugs 11 Specifically glucocorticoids are begun in patients manifesting with nephrotic range proteinuria gt 3 5 g day 35 36 For patients who maintain nephrotic range proteinuria despite glucocorticoids or for patients who demonstrate glucocorticoid intolerance calcineurin inhibitors e g tacrolimus are initiated 36 Successful treatment is defined as a drop in proteinuria to sub nephrotic ranges 6 The treatment of secondary FSGS involves addressing the particular toxic or stress agent 35 Prognosis editThe majority of untreated cases of FSGS will progress to end stage kidney disease 37 Important prognostic factors include the degree of proteinuria and initial response to therapy Patients with nephrotic range gt 3 5 g day proteinuria have over a 50 rate of progression to end stage kidney disease at 10 years 6 Only 15 of patients with sub nephrotic ranges of proteinuria progress to end stage renal failure at 10 years 6 Initial response to therapy also dictates long term outcomes Those defined as having a complete response typically manifest a proteinuria of lt 300 mg day those with a partial response manifest a sub nephrotic range of proteinuria lt 3 5 g day 38 Either complete or partial response is associated with 80 kidney survival at 10 years compared with about 50 among non responsive patients 38 Epidemiology editFSGS accounts for 35 of all cases of nephrotic syndrome making it one of the most common causes of nephrotic syndrome in the United States 8 FSGS accounts for 2 of all cases of kidney failure 4 African American patients have four times the likelihood of developing FSGS Men are about two times as likely to develop FSGS compared to women 12 Notable cases editAlonzo Mourning Sean Elliott Andy ColeSee also editGlomerulonephritis Nephrotic syndromeReferences edit a b focal segmental glomerulosclerosis at Dorland s Medical Dictionary a b c d e f Rosenberg Avi Z Kopp Jeffrey B 2017 03 07 Focal Segmental Glomerulosclerosis Clinical Journal of the American Society of Nephrology 12 3 502 517 doi 10 2215 CJN 05960616 ISSN 1555 9041 PMC 5338705 PMID 28242845 a b D Agati V The many masks of focal segmental glomerulosclerosis Kidney Int 1994 Oct 46 4 1223 41 doi 10 1038 ki 1994 388 PMID 7861720 a b Kitiyakara C Eggers P Kopp JB Twenty one year trend in ESRD due to focal segmental glomerulosclerosis in the United States Am J Kidney Dis 2004 Nov 44 5 815 25 PMID 15492947 a b c d e f Rydel JJ Korbet SM Borok RZ Schwartz MM Focal segmental glomerular sclerosis in adults presentation course and response to treatment Am J Kidney Dis 1995 Apr 25 4 534 42 doi 10 1016 0272 6386 95 90120 5 PMID 7702047 a b c d Korbet SM Schwartz MM Lewis EJ Primary focal segmental glomerulosclerosis clinical course and response to therapy Am J Kidney Dis 1994 Jun 23 6 773 83 doi 10 1016 s0272 6386 12 80128 4 PMID 8203357 a b c Focal segmental glomerulosclerosis FSGS www kidneyfund org 2021 10 28 Retrieved 2023 11 14 a b Haas M Meehan SM Karrison TG Spargo BH Changing etiologies of unexplained adult nephrotic syndrome a comparison of renal biopsy findings from 1976 1979 and 1995 1997 Am J Kidney Dis 1997 Nov 30 5 621 31 doi 10 1016 s0272 6386 97 90485 6 PMID 9370176 a b c Fogo AB Causes and pathogenesis of focal segmental glomerulosclerosis Nat Rev Nephrol 2015 Feb 11 2 76 87 doi 10 1038 nrneph 2014 216 Epub 2014 Dec 2 PMID 25447132 PMCID PMC4772430 a b c Kiffel J Rahimzada Y Trachtman H Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients Adv Chronic Kidney Dis 2011 Sep 18 5 332 8 doi 10 1053 j ackd 2011 03 005 PMID 21896374 PMCID PMC3709971 a b Campbell KN Tumlin JA Protecting Podocytes A Key Target for Therapy of Focal Segmental Glomerulosclerosis Am J Nephrol 2018 47 Suppl 1 Suppl 1 14 29 doi 10 1159 000481634 Epub 2018 May 31 PMID 29852493 PMCID PMC6589822 a b Tucker JK Focal segmental glomerulosclerosis in African Americans Am J Med Sci 2002 Feb 323 2 90 3 doi 10 1097 00000441 200202000 00006 PMID 11863085 Kitiyakara C Kopp JB Eggers P Trends in the epidemiology of focal segmental glomerulosclerosis Semin Nephrol 2003 Mar 23 2 172 82 doi 10 1053 snep 2003 50025 PMID 12704577 Wallace MA Anatomy and physiology of the kidney AORN J 1998 Nov 68 5 800 803 16 819 20 quiz 821 4 doi 10 1016 s0001 2092 06 62377 6 PMID 9829131 Pollak MR Quaggin SE Hoenig MP Dworkin LD The glomerulus the sphere of influence Clin J Am Soc Nephrol 2014 Aug 7 9 8 1461 9 doi 10 2215 CJN 09400913 Epub 2014 May 29 PMID 24875196 PMCID PMC4123398 Tojo A Kinugasa S Mechanisms of glomerular albumin filtration and tubular reabsorption Int J Nephrol 2012 2012 481520 doi 10 1155 2012 481520 Epub 2012 May 20 PMID 22685655 PMCID PMC3363986 Nagata M Podocyte injury and its consequences Kidney Int 2016 Jun 89 6 1221 30 doi 10 1016 j kint 2016 01 012 Epub 2016 Mar 19 PMID 27165817 Wang CS Greenbaum LA Nephrotic Syndrome Pediatr Clin North Am 2019 Feb 66 1 73 85 doi 10 1016 j pcl 2018 08 006 PMID 30454752 Focal Segmental Glomerulosclerosis FSGS Cleveland Clinic Retrieved 2022 06 30 Ichikawa I Fogo A Focal segmental glomerulosclerosis Pediatr Nephrol 1996 Jun 10 3 374 91 doi 10 1007 BF00866790 PMID 8792409 a b Nagata M Kobayashi N Hara S Focal segmental glomerulosclerosis why does it occur segmentally Pflugers Arch 2017 Aug 469 7 8 983 988 doi 10 1007 s00424 017 2023 x Epub 2017 Jun 29 PMID 28664408 a b c De Vriese AS Sethi S Nath KA et al Differentiating Primary Genetic and Secondary FSGS in Adults A Clinicopathologic Approach J Am Soc Nephrol 2018 29 759 Rennke HG Klein PS Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis Am J Kidney Dis 1989 13 443 a b Helal I Fick Brosnahan GM Reed Gitomer B Schrier RW Glomerular hyperfiltration definitions mechanisms and clinical implications Nat Rev Nephrol 2012 Feb 21 8 5 293 300 doi 10 1038 nrneph 2012 19 PMID 22349487 Dubrow A Mittman N Ghali V Flamenbaum W The changing spectrum of heroin associated nephropathy Am J Kidney Dis 1985 5 36 Kasiske BL Crosson JT Renal disease in patients with massive obesity Arch Intern Med 1986 146 1105 Philippe A Nevo F Esquivel EL Reklaityte D Gribouval O Tete MJ Loirat C Dantal J Fischbach M Pouteil Noble C Decramer S Hoehne M Benzing T Charbit M Niaudet P Antignac C Nephrin mutations can cause childhood onset steroid resistant nephrotic syndrome J Am Soc Nephrol 2008 Oct 19 10 1871 8 doi 10 1681 ASN 2008010059 Epub 2008 Jul 9 PMID 18614772 PMCID PMC2551572 Boute N Gribouval O Roselli S Benessy F Lee H Fuchshuber A Dahan K Gubler MC Niaudet P Antignac C NPHS2 encoding the glomerular protein podocin is mutated in autosomal recessive steroid resistant nephrotic syndrome Nat Genet 2000 Apr 24 4 349 54 doi 10 1038 74166 Erratum in Nat Genet 2000 May 25 1 125 PMID 10742096 Brown EJ Schlondorff JS Becker DJ Tsukaguchi H Tonna SJ Uscinski AL Higgs HN Henderson JM Pollak MR Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis Nat Genet 2010 Jan 42 1 72 6 doi 10 1038 ng 505 Epub 2009 Dec 20 Erratum in Nat Genet 2010 Apr 42 4 361 Tonna Stephen J added PMID 20023659 PMCID PMC2980844 Chang Anthony Robbins amp Cotran Pathologic Basis of Disease Chapter 20 895 952 Fuiano G Comi N Magri P et al Serial morphometric analysis of sclerotic lesions in primary focal segmental glomerulosclerosis J Am Soc Nephrol 1996 7 49 a b Schwartz MM Korbet SM Primary focal segmental glomerulosclerosis pathology histological variants and pathogenesis Am J Kidney Dis 1993 22 874 Cutrim EMM Neves PDMM Campos MAG Wanderley DC Teixeira Junior AAL Muniz MPR et al 2022 Collapsing Glomerulopathy A Review by the Collapsing Brazilian Consortium Front Med Lausanne 9 846173 doi 10 3389 fmed 2022 846173 PMC 8927620 PMID 35308512 a href Template Cite journal html title Template Cite journal cite journal a CS1 maint multiple names authors list link CC BY 4 0 license Thomas DB Franceschini N Hogan SL et al 2006 Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants Kidney Int 69 5 920 6 doi 10 1038 sj ki 5000160 PMID 16518352 a b Chen YM Liapis H Focal segmental glomerulosclerosis molecular genetics and targeted therapies BMC Nephrol 2015 Jul 9 16 101 doi 10 1186 s12882 015 0090 9 PMID 26156092 PMCID PMC4496884 a b Raina R Wang J Sharma A Chakraborty R Extracorporeal Therapies in the Treatment of Focal Segmental Glomerulosclerosis Blood Purif 2020 49 5 513 523 doi 10 1159 000506277 Epub 2020 Feb 19 PMID 32074606 Deegens JK Assmann KJ Steenbergen EJ Hilbrands LB Gerlag PG Jansen JL Wetzels JF Idiopathic focal segmental glomerulosclerosis a favourable prognosis in untreated patients Neth J Med 2005 Nov 63 10 393 8 PMID 16301760 a b Troyanov S Wall CA Miller JA Scholey JW Cattran DC Toronto Glomerulonephritis Registry Group Focal and segmental glomerulosclerosis definition and relevance of a partial remission J Am Soc Nephrol 2005 Apr 16 4 1061 8 doi 10 1681 ASN 2004070593 Epub 2005 Feb 16 PMID 15716334 External links edit Retrieved from https en wikipedia org w index php title Focal segmental glomerulosclerosis amp oldid 1192844759, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.